Search

Your search keyword '"Hindi N"' showing total 257 results
Start Over Author "Hindi N"
257 results on '"Hindi N"'

1. The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules

Author

Saad M. Alqahtani, MD, Saif S. Al-Sobhi, MD, Mohammed A. Alturiqy, MD, Riyadh I. Alsalloum, MD, and Hindi N. Al-Hindi, MD

Subjects
American College of Radiology Thyroid Imaging Reporting and Data System, Atypia of undetermined significance/follicular lesion of undetermined significance, Bethesda III, Medicine (General), R5-920
Abstract

الملخص: أهداف البحث: النوع ذو الأهمية غير المحددة أو الآفة الجريبية ذات الأهمية غير المحددة هي فئة غير متجانسة في علم الخلايا الشفط بالإبرة الدقيقة ، والتي لا تزال إدارتها مثيرة للجدل. تكمن الأهمية السريرية لهذه المجموعة في استبعاد الأورام الخبيثة. هدفت الدراسة الحالية إلى تحديد مدى صلاحية إرشادات نظام البيانات وتقارير التصوير الدرقي للكلية الأمريكية للأشعة (2017) في التنبؤ بالأورام الخبيثة على وجه التحديد في هذه الفئة. طريقة البحث: استخدمت هذه الدراسة مجموعة من دراسة سابقة بأثر رجعي من قبل المؤلفين. تضمنت هذه الدراسة الأتراب بأثر رجعي التي مدتها أربع سنوات جميع الحالات التي تم تشغيلها مع تشخيص خلوي لأنماط ذات أهمية غير محددة أو آفة جرابية ذات أهمية غير محددة. ضمت الدراسة 110 حالة مع التشخيصات النسيجية المرضية النهائية الموثقة والفحوصات بالموجات فوق الصوتية. النتائج: شملت الدراسة 83 أنثى (75.5٪) و 27 ذكر (24.5٪) مريض. كان الخطر الإجمالي للأورام الخبيثة في النوع ذي الأهمية غير المحددة أو الآفة الجريبية ذات الأهمية غير المحددة لعقيدات الغدة الدرقية 47.3 ٪. كانت نسبة الأورام الخبيثة في نظام الإبلاغ والتصوير بالغدة الدرقية بالكلية الأمريكية للأشعة 3، و 4، و 5 كالتالي: 43.5٪ ، 49.4٪ ، 40٪ على التوالي. لم تحقق العلاقة بين الإبلاغ عن تصوير الغدة الدرقية ونظام البيانات وعلم الأمراض النهائي دلالة إحصائية. الاستنتاجات: يعد فحص الخلايا بالإبرة الدقيقة المتكرر مع وجود نوع أولي ذي أهمية غير محددة أو آفة جرابية ذات عقيدات ذات أهمية غير محددة أمرا بالغ الأهمية. أشارت النتائج التي توصلنا إليها إلى أن نظام بيانات وتقارير تصوير الغدة الدرقية بالكلية الأمريكية للأشعة لم يساهم في التقسيم الطبقي لمخاطر الإصابة بالسرطان لأنواع ذات أهمية غير محددة أو آفة جرابية من عقيدات ذات أهمية غير محددة. مطلوب دراسة مستقبلية كبيرة متعددة المؤسسات لتحديد مدى صحتها وما إذا كانت الأدوات السريرية أو الخلوية أو الجزيئية أو البيوكيميائية الأخرى المساعدة يمكن أن تساعد في إدارة هذه العقيدات غير المتجانسة. Abstract: Objectives: Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) is a heterogeneous category of fine needle aspiration cytology (FNAC); the management of this condition remains controversial. The clinical significance of such patients relies on the exclusion of malignancy. In this study, we aimed to determine the validity of the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) (2017) for predicting malignancy in this specific category of patients. Methods: In this study, we analysed a cohort of patients from our previous retrospective study. This four-year retrospective cohort study included all cases undergoing surgery with a cytological diagnosis of AUS/FLUS. We enrolled 110 cases with documented final histopathological diagnoses and ultrasound examinations. Results: The study included 83 females (75.5%) and 27 males (24.5%). The overall risk of malignancy (ROM) for AUS/FLUS thyroid nodules was 47.3%. The ROMs of TI-RADS 3 (TR3), TI-RADS 4 (TR4), and TI-RADS 5 (TR5) were 43.5%, 49.4% and 40%, respectively. There was no significant association between TI-RADS and final pathological analysis. Conclusions: Repeated FNAC with initial AUS/FLUS nodules is crucial. Our findings showed that ACR TI-RADS did not contribute to the cancer risk stratification of AUS/FLUS nodules. A large prospective multi-institutional study is now required to determine the validity of ACR TI-RADS and whether other adjunct clinical, cytological, molecular, or biochemical tools could facilitate the management of patients with these heterogeneous nodules.

Published
2023
Full Text
View/download PDF

2. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry

Author

Hindi, N., Razak, A., Rosenbaum, E., Jonczak, E., Hamacher, R., Rutkowski, P., Bhadri, V.A., Skryd, A., Brahmi, M., Alshibany, A., Jagodzinska-Mucha, P., Bauer, S., Connolly, E., Gelderblom, H., Boye, K., Henon, C., Bae, S., Bogefors, K., Vincenzi, B., Martinez-Trufero, J., Lopez-Martin, J.A., Redondo, A., Valverde, C., Blay, J.-Y., Moura, D.S., Gutierrez, A., Tap, W., and Martin-Broto, J.

Published
2023
Full Text
View/download PDF

5. SELNET clinical practice guidelines for bone sarcoma

Author

Blay, JY, Palmerini, E., Bollard, J., Aguiar, S., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., CHS, Caro-Sánchez, Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, V, Chacón, M., Clara-Altamirano, MA, Collini, P., Correa Genoroso, R., Costa, FD, Cuellar, M., dei Tos, AP, Dominguez Malagon, HR, Donati, DM, Dufresne, A., Eriksson, M., Farias-Loza, M., Frezza, AM, Frisoni, T., Garcia-Ortega, DY, Gerderblom, H., Gouin, F., Gómez-Mateo, MC, Gronchi, A., Haro, J., Hindi, N., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes, A., Lopes David, BB, Lopez-Pousa, A., Lutter, G., Maki, RG, Martinez-Said, H., Martinez-Tlahuel, JL, Mello, CA, Morales Pérez, JM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Santos, TG, Scotlandi, K., MLG, Silva, Soulé, T., Stacchiotti, S., Valverde, CM, Waisberg, F., Zamora Estrada, E., and Martin-Broto, J.

Published
2022
Full Text
View/download PDF

6. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

Author

Stacchiotti, S., Miah, A.B., Frezza, A.M., Messiou, C., Morosi, C., Caraceni, A., Antonescu, C.R., Bajpai, J., Baldini, E., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Callegaro, D., De Alava, E., Deoras-Sutliff, M., Dufresne, A., Eriksson, M., Errani, C., Fedenko, A., Ferraresi, V., Ferrari, A., Fletcher, C.D.M., Garcia del Muro, X., Gelderblom, H., Gladdy, R.A., Gouin, F., Grignani, G., Gutkovich, J., Haas, R., Hindi, N., Hohenberger, P., Huang, P., Joensuu, H., Jones, R.L., Jungels, C., Kasper, B., Kawai, A., Le Cesne, A., Le Grange, F., Leithner, A., Leonard, H., Lopez Pousa, A., Martin Broto, J., Merimsky, O., Merriam, P., Miceli, R., Mir, O., Molinari, M., Montemurro, M., Oldani, G., Palmerini, E., Pantaleo, M.A., Patel, S., Piperno-Neumann, S., Raut, C.P., Ravi, V., Razak, A.R.A., Reichardt, P., Rubin, B.P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sapisochin, G., Sbaraglia, M., Scheipl, S., Schöffski, P., Strauss, D., Strauss, S.J., Sundby Hall, K., Tap, W.D., Trama, A., Tweddle, A., van der Graaf, W.T.A., Van De Sande, M.A.J., Van Houdt, W., van Oortmerssen, G., Wagner, A.J., Wartenberg, M., Wood, J., Zaffaroni, N., Zimmermann, C., Casali, P.G., Dei Tos, A.P., and Gronchi, A.

Published
2021
Full Text
View/download PDF

7. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Buonadonna, A., De Álava, E., Dei Tos, A.P., Del Muro, X.G., Dufresne, A., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Strauss, S.J., Hall, K Sundby, Trama, A., Unk, M., van de Sande, M.A.J., van der Graaf, W.T.A., van Houdt, W.J., Frebourg, T., Gronchi, A., and Stacchiotti, S.

Published
2021
Full Text
View/download PDF

8. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Author

Demetri, G.D., Antonescu, C.R., Bjerkehagen, B., Bovée, J.V.M.G., Boye, K., Chacón, M., Dei Tos, A.P., Desai, J., Fletcher, J.A., Gelderblom, H., George, S., Gronchi, A., Haas, R.L., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Judson, I., Kang, Y.-K., Kawai, A., Lazar, A.J., Le Cesne, A., Maestro, R., Maki, R.G., Martín, J., Patel, S., Penault-Llorca, F., Premanand Raut, C., Rutkowski, P., Safwat, A., Sbaraglia, M., Schaefer, I.-M., Shen, L., Serrano, C., Schöffski, P., Stacchiotti, S., Sundby Hall, K., Tap, W.D., Thomas, D.M., Trent, J., Valverde, C., van der Graaf, W.T.A., von Mehren, M., Wagner, A., Wardelmann, E., Naito, Y., Zalcberg, J., and Blay, J.-Y.

Published
2020
Full Text
View/download PDF

9. The sacral chordoma margin

Author

Radaelli, S., Fossati, P., Stacchiotti, S., Akiyama, T., Asencio, J.M., Bandiera, S., Boglione, A., Boland, P., Bolle, S., Bruland, Ø., Brunello, A., Bruzzi, P., Campanacci, D., Cananzi, F., Capanna, R., Casadei, R., Cordoba, A., Court, C., Dei Tos, A.P., DeLaney, T.F., De Paoli, A., De Pas, T.M., Desai, A., Di Brina, L., Donati, D.M., Fabbri, N., Fiore, M.R., Frezza, A., Gambarotti, M., Gasbarrini, A., Georg, P., Grignani, G., Hindi, N., Hug, E.B., Jones, R., Kawai, A., Krol, A.D., Le Grange, F., Luzzati, A., Marquina, G., Martin-Benlloch, J.A., Mazzocco, K., Navarria, F., Navarria, P., Parchi, P.D., Patel, S., Pennacchioli, E., Petrongari, M.G., Picci, P., Pollock, R., Porcu, L., Quagliuolo, V., Sangalli, C., Scheipl, S., Scotto, G.M., Spalek, M., Steinmeier, T., Timmermann, B., Trama, A., Uhl, M., Valverde, C., Varga, P.P., Verges, R., Weber, D.C., Zoccali, C., Casali, P.G., Sommer, J., and Gronchi, A.

Published
2020
Full Text
View/download PDF

11. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group

Author

Stacchiotti, S., Gronchi, A., Fossati, P., Akiyama, T., Alapetite, C., Baumann, M., Blay, J.Y., Bolle, S., Boriani, S., Bruzzi, P., Capanna, R., Caraceni, A., Casadei, R., Colia, V., Debus, J., Delaney, T., Desai, A., Dileo, P., Dijkstra, S., Doglietto, F., Flanagan, A., Froelich, S., Gardner, P.A., Gelderblom, H., Gokaslan, Z.L., Haas, R., Heery, C., Hindi, N., Hohenberger, P., Hornicek, F., Imai, R., Jeys, L., Jones, R.L., Kasper, B., Kawai, A., Krengli, M., Leithner, A., Logowska, I., Martin Broto, J., Mazzatenta, D., Morosi, C., Nicolai, P., Norum, O.J., Patel, S., Penel, N., Picci, P., Pilotti, S., Radaelli, S., Ricchini, F., Rutkowski, P., Scheipl, S., Sen, C., Tamborini, E., Thornton, K.A., Timmermann, B., Torri, V., Tunn, P.U., Uhl, M., Yamada, Y., Weber, D.C., Vanel, D., Varga, P.P., Vleggeert-Lankamp, C.L.A., Casali, P.G., and Sommer, J.

Published
2017
Full Text
View/download PDF

12. Gastrointestinal stromal tumours

Author

Casali, P.G., Blay, J.Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Strauss, S.J., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Gronchi, A., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Alava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., Medical Oncology, ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), and Man, Biomaterials and Microbes (MBM)

Subjects
GIST, clinical practice guidelines, gastrointestinal stromal tumour, surgery, tyrosine kinase inhibitor, Oncology, Medizin, Hematology, clinical practice guideline
Abstract

Gastrointestinal stromal tumours (GISTs) are malignant mesenchymal tumours with a variable clinical behaviour, marked by differentiation towards the interstitial cells of Cajal.1 GISTs belong to the family of soft tissue sarcomas (STSs) but are treated separately due to their peculiar histogenesis, clinical behaviour and specific therapy. This European Society for Medical Oncology (ESMO)–European Reference Network for Rare Adult Solid Cancers (EURACAN)–European Reference Network for Genetic Tumour Risk Syndromes (GENTURIS) Clinical Practice Guideline (CPG) will cover GISTs while other STSs are covered in the ESMO–EURACAN–European Reference Network for Paediatric Oncology (ERN PaedCan)–GENTURIS STS CPG.

Published
2022

13. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Pousa, A.L., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Ladenstein, R., Casali, P.G., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, ERN PaedCan, European Society for Medical Oncology, Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Alava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), and Man, Biomaterials and Microbes (MBM)

Subjects
medicine.medical_specialty, diagnosis, Medizin, bone sarcoma, Bone Neoplasm, Bone Sarcoma, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, follow-up, medicine, 030304 developmental biology, Osteosarcoma, 0303 health sciences, treatment, business.industry, Sarcoma, Hematology, Guideline, clinical practice guideline, management, 3. Good health, Clinical Practice, diagnosi, Oncology, Diagnosis treatment, 030220 oncology & carcinogenesis, Radiology, business, Human
Abstract

A. Kawai43, K. Kopeckova44, D. A. Krakorova45, A. Le Cesne46, F. Le Grange1, E. Legius47, A. Leithner48, A. Lopez Pousa49, J. Martin-Broto36, O. Merimsky50, C. Messiou51, A. B. Miah52, O. Mir53, M. Montemurro54, B. Morland55, C. Morosi56, E. Palmerini57, M. A. Pantaleo58, R. Piana59, S. Piperno-Neumann60, P. Reichardt61, P. Rutkowski62, A. A. Safwat63, C. Sangalli64, M. Sbaraglia19, S. Scheipl48, P. Schoffski65, S. Sleijfer66, D. Strauss67, K. Sundby Hall13, A. Trama68, M. Unk69, M. A. J. van de Sande70, W. T. A. van der Graaf66,71, W. J. van Houdt72, T. Frebourg73x, R. Ladenstein41z, P. G. Casali2,74z &

Published
2021

14. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]

Author

Blay, J.Y., primary, Hindi, N., additional, Bollard, J., additional, Aguiar, S., additional, Angel, M., additional, Araya, B., additional, Badilla, R., additional, Bernabeu, D., additional, Campos, F., additional, Caro-Sánchez, C.H.S., additional, Carvajal, B., additional, Carvajal Montoya, A., additional, Casavilca-Zambrano, S., additional, Castro-Oliden, V., additional, Chacón, M., additional, Clara, M., additional, Collini, P., additional, Correa Genoroso, R., additional, Costa, F.D., additional, Cuellar, M., additional, dei Tos, A.P., additional, Dominguez Malagon, H.R., additional, Donati, D., additional, Dufresne, A., additional, Eriksson, M., additional, Farias-Loza, M., additional, Fernandez, P., additional, Frezza, A.M., additional, Frisoni, T., additional, Garcia-Ortega, D.Y., additional, Gelderblom, H., additional, Gouin, F., additional, Gómez-Mateo, M.C., additional, Gronchi, A., additional, Haro, J., additional, Huanca, L., additional, Jimenez, N., additional, Karanian, M., additional, Kasper, B., additional, Lopes David, B.B., additional, Lopez-Pousa, A., additional, Lutter, G., additional, Martinez-Said, H., additional, Martinez-Tlahuel, J., additional, Mello, C.A., additional, Morales Pérez, J.M., additional, Moura David, S., additional, Nascimento, A.G., additional, Ortiz-Cruz, E.J., additional, Palmerini, E., additional, Patel, S., additional, Pfluger, Y., additional, Provenzano, S., additional, Righi, A., additional, Rodriguez, A., additional, Salas, R., additional, Santos, T.T.G., additional, Scotlandi, K., additional, Soule, T., additional, Stacchiotti, S., additional, Valverde, C., additional, Waisberg, F., additional, Zamora Estrada, E., additional, and Martin-Broto, J., additional

Published
2023
Full Text
View/download PDF

15. Hidradenitis suppurativa secondary to treatment with a gamma secretase inhibitor.

Author

Ríos‐Viñuela, E., Hoyas‐Rodríguez, I., Cullen‐Aravena, D., Martín‐Broto, J., Hindi, N., Eraña, I., and Requena, L.

Subjects
HIDRADENITIS suppurativa, SECRETASE inhibitors, TOPICAL drug administration, DESMOID tumors, THERAPEUTICS
Abstract

This article discusses a case study of a patient who developed hidradenitis suppurativa (HS)-like inflammatory lesions as a result of treatment with a gamma secretase inhibitor (GSC). HS is a chronic inflammatory disease of the hair follicle, and the development of follicular plugs and subsequent inflammation are believed to play a role in its development. The patient in the case study experienced skin lesions after starting GSC inhibition therapy for a desmoid tumor. The article highlights the importance of properly identifying and managing skin toxicity associated with GSC inhibitors and calls for further research and effective management strategies for this novel category of HS. [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. ISG15 as a prognostic biomarker in solitary fibrous tumour

Author

Mondaza Hernandez, J.L., primary, Moura, D.S., additional, Lopez-Alvarez, M., additional, Sanchez-Bustos, P., additional, Blanco-Alcaina, E., additional, Castilla-Ramirez, C., additional, Collini, P., additional, Merino-Garcia, J., additional, Zamora, J., additional, Carrillo-Garcia, J., additional, Maestro, R., additional, Hindi, N., additional, Garcia-Foncillas, J., additional, and Martin-Broto, J., additional

Published
2022
Full Text
View/download PDF

20. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

Author

Martin-Broto, J, Redondo, A, Valverde, C, Vaz, M A, Mora, J, Garcia del Muro, X, Gutierrez, A, Tous, C, Carnero, A, Marcilla, D, Carranza, A, Sancho, P, Martinez-Trufero, J, Diaz-Beveridge, R, Cruz, J, Encinas, V, Taron, M, Moura, D S, Luna, P, Hindi, N, and Lopez-Pousa, A

Published
2017
Full Text
View/download PDF

21. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10

Author

Blay, J.Y., Palmerini, E., Bollard, J., Aguiar, S., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., Chs, Caro-Sánchez, Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, 5th, Chacón, M., Clara-Altamirano, M.A., Collini, P., Correa Genoroso, R., Costa, F.D., Cuellar, M., Dei Tos, A.P., Dominguez Malagon, H.R., Donati, D.M., Dufresne, A., Eriksson, M., Farias-Loza, M., Frezza, A.M., Frisoni, T., Garcia-Ortega, D.Y., Gerderblom, H., Gouin, F., Gómez-Mateo, M.C., Gronchi, A., Haro, J., Hindi, N., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes, A., Lopes David, B.B., Lopez-Pousa, A., Lutter, G., Maki, R.G., Martinez-Said, H., Martinez-Tlahuel, J.L., Mello, C.A., Morales Pérez, J.M., Moura, D.S., Nakagawa, S.A., Nascimento, A.G., Ortiz-Cruz, E.J., Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Santos, T.G., Scotlandi, K., Mlg, Silva, Soulé, T., Stacchiotti, S., Valverde, C.M., Waisberg, F., Zamora Estrada, E., and Martin-Broto, J.

Published
2022
Full Text
View/download PDF

22. Soft tissue and visceral sarcomas

Author

Gronchi, A., Miah, A.B., DeiTos, A.P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., DeAlava, E., Muro, X.G. del, Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, LeGrange, F., Legius, E., Leithner, A., Lopez-Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Strauss, S., SundbyHall, K., Trama, A., Unk, M., VandeSande, M.A.J., VanderGraaf, W.T.A., Houdt, W.J. van, Frebourg, T., Casali, P.G., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), Man, Biomaterials and Microbes (MBM), Gronchi A., Miah A.B., Dei Tos A.P., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., De Alava E., Del Muro X.G., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Strauss S., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Casali P.G., and Stacchiotti S.

Subjects
sarcoma, uterine sarcoma, treatment, diagnosis, desmoid, Medizin, Sarcoma, Soft Tissue Neoplasms, Hematology, Clinical Practice Guideline, Soft tissue sarcomas, retroperitoneal sarcoma, Retroperitoneal Sarcoma, soft tissue sarcomas, Follow-Up Studie, Desmoid, Uterine Sarcoma, follow-up, management, Oncology, soft tissue sarcoma, Human
Abstract

ispartof: ANNALS OF ONCOLOGY vol:32 issue:11 pages:1348-1365 ispartof: location:England status: published

Published
2021

23. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

Author

Vincenzi, B., Napolitano, A., Fiocco, M., Mir, O., Rutkowski, P., Blay, J.Y., Reichardt, P., Joensuu, H., Fumagalli, E., Gennatas, S., Hindi, N., Nannini, M., Ceruso, M. Spalato, Italiano, A., Grignani, G., Brunello, A., Gasperoni, S., Pas, T. de, Badalamenti, G., Pantaleo, M.A., Houdt, W.J. van, IJzerman, Nikki S., Steeghs, N., Gelderblom, H., Desar, I.M.E., Falkenhorst, J., Silletta, M., Sbaraglia, M., Tonini, G., Martin-Broto, J., Hohenberger, P., Cesne, A. Le, Jones, R.L., Tos, A.P. Dei, Gronchi, A., Bauer, S., Casali, P.G., Vincenzi, B., Napolitano, A., Fiocco, M., Mir, O., Rutkowski, P., Blay, J.Y., Reichardt, P., Joensuu, H., Fumagalli, E., Gennatas, S., Hindi, N., Nannini, M., Ceruso, M. Spalato, Italiano, A., Grignani, G., Brunello, A., Gasperoni, S., Pas, T. de, Badalamenti, G., Pantaleo, M.A., Houdt, W.J. van, IJzerman, Nikki S., Steeghs, N., Gelderblom, H., Desar, I.M.E., Falkenhorst, J., Silletta, M., Sbaraglia, M., Tonini, G., Martin-Broto, J., Hohenberger, P., Cesne, A. Le, Jones, R.L., Tos, A.P. Dei, Gronchi, A., Bauer, S., and Casali, P.G.

Abstract

Item does not contain fulltext, PURPOSE: The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a large multi-institutional European cohort. EXPERIMENTAL DESIGN: Data from 185 patients were retrospectively collected in 23 European GIST reference centers. Propensity score matching (PSM) and inverse-probability of treatment weighting (IPTW) were used to account for confounders. Univariate and multivariate unweighted and weighted Cox proportional hazard regression models were estimated for relapse-free survival (RFS), modified-RFS (mRFS) and imatinib failure-free survival (IFFS). Univariate Cox models were estimated for overall survival. RESULTS: Of the 185 patients, 131 (70.8%) received a starting dose of 400 mg/d and the remaining 54 (29.2%) a dose of 800 mg/d. Baseline characteristics were partially unbalanced, suggesting a potential selection bias. PSM and IPTW analyses showed no advantage of imatinib 800 mg/d. In the weighted multivariate Cox models, high-dose imatinib was not associated with the survival outcomes [RFS: hazard ratio (HR), 1.24; 95% confidence interval (CI), 0.79-1.94; mRFS: HR, 1.69; 95% CI, 0.92-3.10; IFFS: HR, 1.35; 95% CI, 0.79-2.28]. The variables consistently associated with worse survival outcomes were high mitotic index and nongastric tumor location. CONCLUSIONS: In this retrospective series of patients with KIT exon 9-mutated GIST treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes. Prospective evaluation of the more appropriate adjuvant treatment in this setting is warranted.

Published
2022

24. SELNET clinical practice guidelines for soft tissue sarcoma and GIST

Author

Blay, J.Y., primary, Hindi, N., additional, Bollard, J., additional, Aguiar, S., additional, Angel, M., additional, Araya, B., additional, Badilla, R., additional, Bernabeu, D., additional, Campos, F., additional, Caro-Sánchez, C.H.S., additional, Carvajal, B., additional, Carvajal Montoya, A., additional, Casavilca-Zambrano, S., additional, Castro-Oliden, V., additional, Chacón, M., additional, Clara, M., additional, Collini, P., additional, Correa Genoroso, R., additional, Costa, F.D., additional, Cuellar, M., additional, dei Tos, A.P., additional, Dominguez Malagon, H.R., additional, Donati, D., additional, Dufresne, A., additional, Eriksson, M., additional, Farias-Loza, M., additional, Fernandez, P., additional, Frezza, A.M., additional, Frisoni, T., additional, Garcia-Ortega, D.Y., additional, Gelderblom, H., additional, Gouin, F., additional, Gómez-Mateo, M.C., additional, Gronchi, A., additional, Haro, J., additional, Huanca, L., additional, Jimenez, N., additional, Karanian, M., additional, Kasper, B., additional, Lopes David, B.B., additional, Lopez-Pousa, A., additional, Lutter, G., additional, Martinez-Said, H., additional, Martinez-Tlahuel, J., additional, Mello, C.A., additional, Morales Pérez, J.M., additional, Moura David, S., additional, Nascimento, A.G., additional, Ortiz-Cruz, E.J., additional, Palmerini, E., additional, Patel, S., additional, Pfluger, Y., additional, Provenzano, S., additional, Righi, A., additional, Rodriguez, A., additional, Salas, R., additional, Santos, T.T.G., additional, Scotlandi, K., additional, Soule, T., additional, Stacchiotti, S., additional, Valverde, C., additional, Waisberg, F., additional, Zamora Estrada, E., additional, and Martin-Broto, J., additional

Published
2022
Full Text
View/download PDF

25. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P.G., primary, Blay, J.Y., additional, Abecassis, N., additional, Bajpai, J., additional, Bauer, S., additional, Biagini, R., additional, Bielack, S., additional, Bonvalot, S., additional, Boukovinas, I., additional, Bovee, J.V.M.G., additional, Boye, K., additional, Brodowicz, T., additional, Buonadonna, A., additional, De Álava, E., additional, Dei Tos, A.P., additional, Del Muro, X.G., additional, Dufresne, A., additional, Eriksson, M., additional, Fedenko, A., additional, Ferraresi, V., additional, Ferrari, A., additional, Frezza, A.M., additional, Gasperoni, S., additional, Gelderblom, H., additional, Gouin, F., additional, Grignani, G., additional, Haas, R., additional, Hassan, A.B., additional, Hindi, N., additional, Hohenberger, P., additional, Joensuu, H., additional, Jones, R.L., additional, Jungels, C., additional, Jutte, P., additional, Kasper, B., additional, Kawai, A., additional, Kopeckova, K., additional, Krákorová, D.A., additional, Le Cesne, A., additional, Le Grange, F., additional, Legius, E., additional, Leithner, A., additional, Lopez-Pousa, A., additional, Martin-Broto, J., additional, Merimsky, O., additional, Messiou, C., additional, Miah, A.B., additional, Mir, O., additional, Montemurro, M., additional, Morosi, C., additional, Palmerini, E., additional, Pantaleo, M.A., additional, Piana, R., additional, Piperno-Neumann, S., additional, Reichardt, P., additional, Rutkowski, P., additional, Safwat, A.A., additional, Sangalli, C., additional, Sbaraglia, M., additional, Scheipl, S., additional, Schöffski, P., additional, Sleijfer, S., additional, Strauss, D., additional, Strauss, S.J., additional, Hall, K Sundby, additional, Trama, A., additional, Unk, M., additional, van de Sande, M.A.J., additional, van der Graaf, W.T.A., additional, van Houdt, W.J., additional, Frebourg, T., additional, Gronchi, A., additional, and Stacchiotti, S., additional

Published
2022
Full Text
View/download PDF

26. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states

Author

Blay, J-Y, Casali, P, Bouvier, C, Dehais, C, Galloway, I, Gietema, J, Halámková, J, Hindi, N, Idbaih, A, Kinloch, E, Klümpen, H-J, Kolarova, T, Kopeckova, K, Lovey, J, Magalhaes, M, Oselin, K, Piperno-Neumann, S, Ravnsbaek, A, Rogasik, M, Safwat, A, Scheipl, S, Seckl, M, Taylor, J, Temnyk, M, Trama, A, Urbonas, M, Wartenberg, M, Weinman, A, EURACAN Network, Oncology, CCA - Cancer Treatment and Quality of Life, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], University of Milan, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Royal Free Hospital [London, UK], Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Masaryk Memorial Cancer Institute (RECAMO), Hospital Universitario Virgen del Rocío [Sevilla], University of Amsterdam [Amsterdam] (UvA), University Hospital Motol [Prague], National Institute of Oncology [Budapest, Hungary], Centro Hospitalar do Porto, North Estonia Medical Center, Institut Curie [Paris], Aarhus University Hospital, Karl-Franzens-Universität [Graz, Autriche], Charing Cross Hospital & Imperial College, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Kaunas University of Technology (KTU), EURORDIS-Rare Diseases Europe (Bureau de Paris), EURORDIS - Plateforme Maladies Rares [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and University of Graz

Subjects
Cancer Research, medicine.medical_specialty, Statement (logic), MEDLINE, [SDV.CAN]Life Sciences [q-bio]/Cancer, News, GUIDELINES, DIAGNOSIS, 03 medical and health sciences, 0302 clinical medicine, EURACAN Network, Health care, medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, business.industry, Member states, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Family medicine, SURVIVAL, Position paper, SARCOMA PATIENTS, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, BURDEN
Abstract

International audience

Published
2021

27. 1536P Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups

Author

Lacerenza, S., primary, Moura, D., additional, Peña-Chilet, M., additional, Hindi, N., additional, Dopazo, J., additional, Sanchez-Bustos, P., additional, Grignani, G., additional, Martinez-Trufero, J., additional, Redondo, A., additional, Valverde, C., additional, Stacchiotti, S., additional, Lopez Pousa, A., additional, D’Ambrosio, L., additional, Perez-Vega, H., additional, Collini, P., additional, Lopez-Martin, J.A., additional, and Martin Broto, J., additional

Published
2021
Full Text
View/download PDF

28. 1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Author

Martin Broto, J., primary, Valverde, C., additional, Hindi, N., additional, Vincenzi, B., additional, Martinez-Trufero, J., additional, Grignani, G., additional, Italiano, A., additional, Lavernia, J., additional, Gonzalez-Campora, R., additional, Vallejo, A., additional, Hernandez-Jover, D., additional, Gutierrez, A., additional, Serrano, C., additional, Moura, D., additional, Lopez-Guerrero, J.A., additional, Cruz, J., additional, Fernández-Serra, A., additional, Blay, J-Y., additional, Fumagalli, E.R., additional, and Martinez Marin, V., additional

Published
2021
Full Text
View/download PDF

29. GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

Author

Gallego, S., Bernabeu, D., Garrido-Pontnou, M., Guillen, G., Hindi, N., Juan-Ribelles, A., Marquez, C., Mata, C., Orcajo, J., Ramirez, G., Ramos, M., Romagosa, C., Ruano, D., Rubio, P., Verges, R., Valverde, C., GEIS Grp Espanol Invest Sarcomas, and SEHOP Soc Espanola Hematologia Onc

Subjects
Alveolar rhabdomyosarcoma, Embryonal rhabdomyosarcoma, Prognostic factors, Rhabdomyosarcoma
Abstract

Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm.

Published
2021

30. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature

Author

Frezza, A.M., Ravi, V., Vullo, S. Lo, Vincenzi, B., Tolomeo, F., Chen, T.W., Teterycz, P., Baldi, G.G., Italiano, A., Penel, N., Brunello, A., Duffaud, F., Hindi, N., Iwata, S., Smrke, A., Fedenko, A., Gelderblom, H., Graaf, W.T.A. van der, Vozy, A., Connolly, E., Grassi, M., Benjamin, R.S., Broto, J.M., Grignani, G., Jones, R.L., Kawai, A., Tysarowski, A., Mariani, L., Casali, P.G., Stacchiotti, S., Frezza, A.M., Ravi, V., Vullo, S. Lo, Vincenzi, B., Tolomeo, F., Chen, T.W., Teterycz, P., Baldi, G.G., Italiano, A., Penel, N., Brunello, A., Duffaud, F., Hindi, N., Iwata, S., Smrke, A., Fedenko, A., Gelderblom, H., Graaf, W.T.A. van der, Vozy, A., Connolly, E., Grassi, M., Benjamin, R.S., Broto, J.M., Grignani, G., Jones, R.L., Kawai, A., Tysarowski, A., Mariani, L., Casali, P.G., and Stacchiotti, S.

Abstract

Contains fulltext : 238293.pdf (Publisher’s version ) (Open Access), BACKGROUND: This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions. METHODS: Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. RESULTS: Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported. CONCLUSION: Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.

Published
2021

31. 1932P First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma

Author

González, J.A., Sebio, A., Beveridge, R. Díaz, Castellanos, J.F. Orbis, Andújar, R. López, Álvarez, R. Álvarez, Asencio, J. Manuel, Martin-Broto, J., Hindi, N., Jimenez, M., Villarejo-Campos, P., García, C. Serrano, Rodríguez, N., Boix, S. Castro, Campos, A. Perez, Casas, F. Cano, García, J.A. Tornero, Marti, L., Krauel, L., and Pousa, A. Lopez

Published
2023
Full Text
View/download PDF

32. Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study

Author

Fernandez-Serra A, Moura DS, Sanchez-Izquierdo MD, Calabuig-Fariñas S, Lopez-Alvarez M, Martínez-Martínez A, Carrasco-Garcia I, Ramírez-Calvo M, Blanco-Alcaina E, López-Reig R, Obrador-Hevia A, Alemany R, Gutierrez A, Hindi N, Poveda A, Lopez-Guerrero JA, and Martin-Broto J

Subjects
GIST, caspase-3, let-7e, miR-550, prognostic biomarkers
Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore new molecular prognostic biomarkers in localized intestinal high-risk GIST. Paraffin tumor blocks of 14 and 86 patients were used in the discovery and expansion sets, respectively. GeneChip miRNA v3.0 was employed to identify the miRNAs differentially expressed between relapsed and non-relapsed patient samples, which were validated in the expansion set, by qRT-PCR. RT2 Profiler PCR Array was used for the screening of let-7e targets. Expression levels were correlated with relapse-free survival and overall survival. In the discovery set, 39 miRNAs were significantly deregulated, let-7e and miR-550 being the most underexpressed and overexpressed miRNAs in the relapsed group, respectively. In the expansion set, the underexpression of let-7e or the overexpression of 4 of its target genes ( ACVR1B , CASP3 , COL3A1, and COL5A2 ) were statistically associated with worse relapse-free survival. The expression of let-7e and 4 of its target genes are potential prognostic biomarkers in high-risk localized intestinal GIST. The expression of these genes is a potential molecular tool useful for a more accurate prognosis in this subset of GIST patients.

Published
2020

33. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Author

Demetri, GD, Antonescu, CR, Bjerkehagen, B, Bovée, JVMG, Boye, K, Chacón, M, Dei Tos, AP, Desai, J, Fletcher, JA, Gelderblom, H, George, S, Gronchi, A, Haas, RL, Hindi, N, Hohenberger, P, Joensuu, H, Jones, RL, Judson, I, Kang, YK, Kawai, A, Lazar, AJ, Le Cesne, A, Maestro, R, Maki, RG, Martín, J, Patel, S, Penault-Llorca, F, Premanand Raut, C, Rutkowski, P, Safwat, A, Sbaraglia, M, Schaefer, IM, Shen, L, Serrano, C, Schöffski, P, Stacchiotti, S, Sundby Hall, K, Tap, WD, Thomas, DM, Trent, J, Valverde, C, van der Graaf, WTA, von Mehren, M, Wagner, A, Wardelmann, E, Naito, Y, Zalcberg, J, Blay, JY, Demetri, GD, Antonescu, CR, Bjerkehagen, B, Bovée, JVMG, Boye, K, Chacón, M, Dei Tos, AP, Desai, J, Fletcher, JA, Gelderblom, H, George, S, Gronchi, A, Haas, RL, Hindi, N, Hohenberger, P, Joensuu, H, Jones, RL, Judson, I, Kang, YK, Kawai, A, Lazar, AJ, Le Cesne, A, Maestro, R, Maki, RG, Martín, J, Patel, S, Penault-Llorca, F, Premanand Raut, C, Rutkowski, P, Safwat, A, Sbaraglia, M, Schaefer, IM, Shen, L, Serrano, C, Schöffski, P, Stacchiotti, S, Sundby Hall, K, Tap, WD, Thomas, DM, Trent, J, Valverde, C, van der Graaf, WTA, von Mehren, M, Wagner, A, Wardelmann, E, Naito, Y, Zalcberg, J, and Blay, JY

Abstract

Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK) inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and diagnostic complexity of NTRK gene fusions raise a number of questions and challenges for clinicians. To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.

Published
2020

34. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Author

Kamposioras, K., Mauri, D., Papadimitriou, K., Anthoney, A., Hindi, N., Petricevic, B., Dambrosio, M., Valachis, A., Kountourakis, P., Kopecky, J., Kuhar, C.G., Popovic, L., Chilingirova, N.P., Zarkavelis, G., de Mello, R.A., Plavetić, N.D., Christopoulos, C., Mostert, B. (Bianca), Goffin, J. R., Tzachanis, D., Saraireh, H.H., Ma, F, Pavese, I., Tolia, M., Kamposioras, K., Mauri, D., Papadimitriou, K., Anthoney, A., Hindi, N., Petricevic, B., Dambrosio, M., Valachis, A., Kountourakis, P., Kopecky, J., Kuhar, C.G., Popovic, L., Chilingirova, N.P., Zarkavelis, G., de Mello, R.A., Plavetić, N.D., Christopoulos, C., Mostert, B. (Bianca), Goffin, J. R., Tzachanis, D., Saraireh, H.H., Ma, F, Pavese, I., and Tolia, M.

Abstract

Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.

Published
2020
Full Text
View/download PDF

35. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

Author

Mauri, D., Kamposioras, K., Tolia, M., Alongi, F., Tzachanis, D., Petricevic, B., Chilingirova, N., Mihaylova, I., Tsakiridis, T., Salembier, C., Papadimitriou, K., De Mello, R. A., Amaral, G. A., Neves, N. M., Dias, R., Yi, J., Dedic Plavetic, N., Antunac, K., Kountourakis, P., Kopecky, J., Christopoulos, C., Pavese, I., Corradini, S., Zarkavelis, G., Papadaki, A., Gkantaifi, A., Theodorelos, V., Capizzello, A., Lovey, J., Cellini, Francesco, Dambrosio, M., Takeuchi, D., Saraireh, H. H., Rotterud, R., Chojnacka, M., Papachristos, A., Djan, I., Popovic, L., Grasic Kuhar, C., Strojan, P., Hindi, N., Valachis, A., Ahs, M., De Bari, B., Santa Cruz, O., Hameed, H., Takeuchi, E., Apostolidis, K., Cardone, A., Gono, P., Filis, P., Cellini F. (ORCID:0000-0002-2145-2300), Mauri, D., Kamposioras, K., Tolia, M., Alongi, F., Tzachanis, D., Petricevic, B., Chilingirova, N., Mihaylova, I., Tsakiridis, T., Salembier, C., Papadimitriou, K., De Mello, R. A., Amaral, G. A., Neves, N. M., Dias, R., Yi, J., Dedic Plavetic, N., Antunac, K., Kountourakis, P., Kopecky, J., Christopoulos, C., Pavese, I., Corradini, S., Zarkavelis, G., Papadaki, A., Gkantaifi, A., Theodorelos, V., Capizzello, A., Lovey, J., Cellini, Francesco, Dambrosio, M., Takeuchi, D., Saraireh, H. H., Rotterud, R., Chojnacka, M., Papachristos, A., Djan, I., Popovic, L., Grasic Kuhar, C., Strojan, P., Hindi, N., Valachis, A., Ahs, M., De Bari, B., Santa Cruz, O., Hameed, H., Takeuchi, E., Apostolidis, K., Cardone, A., Gono, P., Filis, P., and Cellini F. (ORCID:0000-0002-2145-2300)

Abstract

N/A

Published
2020

36. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Author

Kamposioras, K, Mauri, D, Papadimitriou, K, Anthoney, A, Hindi, N, Petricevic, B, Dambrosio, M, Valachis, A, Kountourakis, P, Kopecky, J, Kuhar, CG, Popovic, L, Chilingirova, NP, Zarkavelis, G, de Mello, RA, Plaveti?, ND, Christopoulos, C, Mostert, Bianca, Goffin, J R, Tzachanis, D, Saraireh, HH, Ma, F, Pavese, I, Tolia, M, Kamposioras, K, Mauri, D, Papadimitriou, K, Anthoney, A, Hindi, N, Petricevic, B, Dambrosio, M, Valachis, A, Kountourakis, P, Kopecky, J, Kuhar, CG, Popovic, L, Chilingirova, NP, Zarkavelis, G, de Mello, RA, Plaveti?, ND, Christopoulos, C, Mostert, Bianca, Goffin, J R, Tzachanis, D, Saraireh, HH, Ma, F, Pavese, I, and Tolia, M

Published
2020

37. LGMD1D myopathy with cytoplasmic and nuclear inclusions in a Saudi family due to DNAJB6 mutation

Author

BOHLEGA, SAEED A., ALFAWAZ, SARAH, ABOU-AL-SHAAR, HUSSAM, AL-HINDI, HINDI N., MURAD, HATEM N., BOHLEGA, MOHAMED S., MEYER, BRIAN F., and MONIES, DOROTA

Subjects
muscular dystrophy, Adult, Cell Nucleus, Inclusion Bodies, Male, Cytoplasm, Heterozygote, Saudi Arabia, cytoplasmic inclusion, Nerve Tissue Proteins, HSP40 Heat-Shock Proteins, Middle Aged, LGMD, Arabs, Pedigree, Phenotype, Muscular Dystrophies, Limb-Girdle, Disease Progression, Humans, Original Article, DNAJB6, LGMD1D, Muscle, Skeletal, Molecular Chaperones
Abstract

Autosomal dominant LGMD1D has been described in multiple families in Asia, Europe, and USA. However, to the best of our knowledge, no cases of LGMD1D have been reported among native Bedouin Saudi families. Fifty Saudi families with LGMD were analyzed and the causative underlying genes were studied utilizing genome wide linkage, homozygosity mapping, and neurological gene panel. We identified one family of a Bedouin origin with LGMD1D. Two patients had progressive proximal and distal weakness, dysphagia, and respiratory symptoms. Creatinine kinase was normal. Muscle biopsy showed marked variation in myofibers size with scattered angular atrophic fiber, necrotic fibers, and myophagocytosis, with red-rimmed vacuoles depicting a sarcoplasmic body. Heterozygous c.C287T (p.P96L) variant in exon 5 of DNAJB6 (NM_005494) gene was found. This change is localized within glycine and phenylalanine rich domain and alter an amino acid residue. Our findings will expand on the existing genotypic and phenotypic spectrum of this disorder and aid in elucidating hidden mechanisms implicated in LGMD1D.

Published
2018

39. 1627MO Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network

Author

Frezza, A.M., primary, Ravi, V., additional, Lo Vullo, S., additional, Tolomeo, F., additional, Wei-Wu Chen, T., additional, Teterycz, P., additional, Baldi, G.G., additional, Italiano, A., additional, Penel, N., additional, Brunello, A., additional, Duffaud, F., additional, Hindi, N., additional, Iwata, S., additional, Smrke, A., additional, Fedenko, A., additional, Gelderblom, H., additional, Van Der Graaf, W., additional, Vozy, A., additional, Vincenzi, B., additional, and Stacchiotti, S., additional

Published
2020
Full Text
View/download PDF

40. 1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)

Author

Broto, J. Martin, primary, Hindi, N., additional, Redondo, A., additional, Morales, J.M., additional, Marcilla, D., additional, Valverde, C., additional, Luna, P., additional, Diaz-Beveritge, R., additional, Martinez-Trufero, J., additional, Lopez-Martin, J.A., additional, Martinez, V., additional, Gutierrez, A., additional, and Lopez-Pousa, A., additional

Published
2020
Full Text
View/download PDF

41. Surgical Outcome of Thyroid Nodules with Atypia of Undetermined Significance and Follicular Lesion of Undetermined Significance in Fine Needle Aspiration Biopsy

Author

Saleh N Najjar, Hindi N Al-Hindi, Riyadh I Alsalloum, Saad Alqahtani, and Saif Alsobhi

Subjects
Thyroid nodules, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Fine-needle aspiration, Follicular neoplasm, 030220 oncology & carcinogenesis, Biopsy, medicine, Atypia, Radiology, Nuclear Medicine and imaging, Surgery, Radiology, business
Abstract

Aim To correlate selected clinical and ultrasonographic (US) characteristics with the final histopathological diagnosis in patients with atypia of undetermined significance (AUS) and follicular lesion of undetermined significance (FLUS), and whether this information can be used in planning the surgical approach. Materials and methods It is a retrospective study including the operated cases of AUS/FLUS from 2011 to 2014 treated at one center. Results This cohort included 87 women and 28 men. To test for independence between categorical variables, the chi-square test was used. There was no significant correlation between age or US variables and final pathological diagnosis. However, final diagnosis of malignancy was higher in men compared with women (64.3 and 41.4% respectively; p = 0.035). Furthermore, a significant association between the diagnosis of repeated fine needle aspiration biopsy (FNAB) and the final pathological diagnosis was noted (benign vs malignant, p = 0.005). Conclusion The FNAB has a significant role in the assessment of thyroid nodules. Our results showed no correlation between age, US variables, and the risk of malignancy. Male gender is associated with higher risk of malignancy. Clinical significance Determining the risk of malignancy and prediction of surgical outcome may help triaging cases for repeat FNA or proceeding to surgery. How to cite this article Alqahtani S, Alsobhi S, Alsalloum RI, Najjar SN, Al-Hindi HN. Surgical Outcome of Thyroid Nodules with Atypia of Undetermined Significance and Follicular Lesion of Undetermined Significance in Fine Needle Aspiration Biopsy. World J Endoc Surg 2017;9(3):100-103.

Published
2017

43. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

Author

Lindner, L.H., Litiere, S., Sleijfer, S., Benson, C., Italiano, A., Kasper, B., Messiou, C., Gelderblom, H., Wardelmann, E., Cesne, A. le, Blay, J.Y., Marreaud, S., Hindi, N., Desar, I.M.E., Gronchi, A., Graaf, W.T.A. van der, and Medical Oncology

Subjects
Adult, Male, Lung Neoplasms, Datasets as Topic, prognostic factors, Sarcoma, Soft Tissue Neoplasms, lung metastases, Kaplan-Meier Estimate, Middle Aged, Prognosis, Progression-Free Survival, EORTC, SDG 3 - Good Health and Well-being, soft tissue sarcoma, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Neoplasm Metastasis, Aged, Proportional Hazards Models, Retrospective Studies
Abstract

The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first-line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first-line chemotherapy. Detailed information from 580 patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much higher compared to non-extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival (OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in STS patients with lung metastases confirms well-known patient factors (such as age and PS), and tumor characteristics (including tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new prognostic factor. Knowledge about these factors may support decision-making within multidisciplinary tumor boards.

Published
2018

44. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Author

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, and Martin-Broto J

Subjects
body regions
Abstract

Purpose: Nilotinib plus doxorubicin showed to be synergistic regarding apoptosis in several sarcoma cell lines. A phase I/II trial was thus designed to explore the feasibility of nilotinib as coadjuvant of doxorubicin by inhibiting MRP-1/P-gp efflux activity. The phase I part of the study is presented here. Patients and Methods: Nilotinib 400 mg/12 hours was administered in fixed dose from day 1 to 6, and doxorubicin on day 5 of each cycle. Three dose escalation levels for doxorubicin at 60, 65, and 75 mg/m(2) were planned. Cycles were repeated every 3 weeks for a total of 4 cycles. Eligible subtypes were retroperitoneal liposarcoma, leiomyosarcoma, and unresectable/metastatic high-grade chondrosarcoma. Results: Thirteen patients were enrolled: 7 chondrosarcoma, 4 liposarcoma, and 2 leiomyosarcoma. In 46 cycles administered, the most relevant grade 3/4 adverse effects per patient were neutropenia 54%, febrile neutropenia 15%, and asthenia 8%. No cardiac toxicity was observed. Only one doselimiting toxicity (febrile neutropenia) was reported in the third dose level. With regard to efficacy, 1 partial response (1 liposarcoma), 9 stable diseases (5 chondrosarcoma, 2 liposarcoma, 1 leiomyosarcoma), and 3 progressive diseases (2 chondrosarcoma and 1 leiomyosarcoma) were present. ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle. Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Pharmacodynamic study supports this concept. The recommended dose for the phase II part for doxorubicin was 75 mg/m(2). (C) 2018 AACR.

Published
2018

45. IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort

Author

Broto, J Martin, primary, Hindi, N., additional, Grignani, G.E., additional, Trufero, J Martinez, additional, Redondo, A., additional, Valverde, C., additional, Pousa, A Lopez, additional, Stacchiotti, S., additional, Palmerini, E., additional, de Alava, E., additional, Moura, D.S., additional, Vega, H Perez, additional, Collini, P., additional, Otero, I., additional, Ledesma, P., additional, Marchesi, E., additional, D’Ambrosio, L., additional, and Martin, J A Lopez, additional

Published
2019
Full Text
View/download PDF

47. Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups

Author

Broto, J Martin, primary, Italiano, A., additional, Alvarez, R M Alvarez, additional, Rincon, I., additional, Peinado, J., additional, Sargos, P., additional, Alvarez, A., additional, Luna, P., additional, Pousa, A Lopez, additional, Redondo, A., additional, Alastuey, I., additional, Isern, J., additional, Belinchon, B., additional, Gutierrez, A., additional, Romagosa, C., additional, Marie, K., additional, Morosi, C., additional, Blay, J.-Y., additional, Gronchi, A., additional, and Hindi, N., additional

Published
2019
Full Text
View/download PDF

48. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

Author

Lindner, L.H. (Lars), Litière, S. (Saskia), Sleijfer, S. (Stefan), Benson, C., Italiano, A., Kasper, B. (B.), Messiou, C. (Christina), Gelderblom, H. (Hans), Wardelmann, E. (Eva), Le Cesne, A. (Axel), Blay, J.Y. (Jean Yves), Marreaud, S. (Sandrine), Hindi, N. (Nadia), Desar, I.M.E. (Ingrid), Gronchi, A. (Alessandro), Graaf, W.T.A. (Winette) van der, Lindner, L.H. (Lars), Litière, S. (Saskia), Sleijfer, S. (Stefan), Benson, C., Italiano, A., Kasper, B. (B.), Messiou, C. (Christina), Gelderblom, H. (Hans), Wardelmann, E. (Eva), Le Cesne, A. (Axel), Blay, J.Y. (Jean Yves), Marreaud, S. (Sandrine), Hindi, N. (Nadia), Desar, I.M.E. (Ingrid), Gronchi, A. (Alessandro), and Graaf, W.T.A. (Winette) van der

Abstract

The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first-line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first-line chemotherapy. Detailed information from 580 patients who had lung metastases only

Published
2018
Full Text
View/download PDF

49. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

Author

Lindner, LH, Litiere, S, Sleijfer, Stefan, Benson, C, Italiano, A, Kasper, B, Messiou, C, Gelderblom, H, Wardelmann, E, le Cesne, A, Blay, JY, Marreaud, S, Hindi, N, Desar, IME, Gronchi, A, van der Graaf, WTA, Lindner, LH, Litiere, S, Sleijfer, Stefan, Benson, C, Italiano, A, Kasper, B, Messiou, C, Gelderblom, H, Wardelmann, E, le Cesne, A, Blay, JY, Marreaud, S, Hindi, N, Desar, IME, Gronchi, A, and van der Graaf, WTA

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results